The Human Variable 

CYNAERA’s Personalized CRISPR Remission™ in melanoma integrates PD-1 edited TIL therapy, tumor microenvironment alignment, and VitalGuard™ modeling to improve durable response prediction.

A new framework for disease prevalence estimation, the Diagnostic Multiplier™ (DM™) adjusts for underdiagnosis, diagnostic variability, and environmental exposure across conditions.

CRISPR Remission™ for Lyme disease introduces a personalized CRISPR framework integrating environmental burden, immune variability, and state-dependent intervention to address persistent Lyme and post-treatment Lyme disease.

CRISPR Remission™ for CRPS integrates gene editing, environmental triggers, and flare-aware timing to enable durable stabilization in complex regional pain syndrome.

State-dependent oral CRISPR delivery framework modeling uptake, EBV targeting, and gene editing efficiency. Explores how immune state, environmental burden, and physiology determine real-world therapeutic success.

Pediatric Long COVID in the U.S. may affect 6–10 Remission in Long COVID is often described as partial, inconsistent, or spontaneous. That framing is misleading. What appears random is often the result of poor temporal measurement. Long COVID is not a static illness state. It is a fluctuating systems condition in which symptom burden, immune signaling, autonomic regulation, vascular tone, and exertional tprevalence, symptoms, underdiagnosis, and public health implications usi